Numerous updates in the glaucoma treatment landscape have had a big impact on patient outcomes. The introduction of minimally invasive glaucoma surgeries (MIGS) and the approval of new drugs with new mechanisms of action, for the first time in decades, have transformed the landscape. Ongoing research into new drug delivery systems is likely to provide more effective and convenient treatments in the future.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Denosumab use was associated with lower 5-year risks of ocular hypertension (OHT) and primary open-angle glaucoma (POAG) than bisphosphonate therapy in adults with osteoporosis, according to a multinational retrospective cohort study published in Investigative Ophthalmology & Visual Science.
This week in ophthalmology: new phase 2/3 data in metastatic uveal melanoma, clinically relevant updates from the European Glaucoma Society (EGS) Congress, phase 3 results for a topical diabetic macular edema (DME) candidate, a bevacizumab resubmission for neovascular age-related macular degeneration (AMD), and a link between dermatitis and retinal detachment risk. Here are five stories to catch up on this week.
Rapid Fire abstracts presented at EGS 2026 highlighted long-term XEN 45 outcomes, AI-supported glaucoma screening and increased post-injection intraocular pressure spike risk in patients with prior glaucoma clinic attendance.
The EGS 2026 plenary session on the 6th edition of the European Glaucoma Society Guidelines1 brought together leading glaucoma specialists to discuss how the updated recommendations can be applied in clinical practice. Chaired by Manuele Michelessi and Fotis Topouzis, the session moved from the broad principles of the new guidelines to practical discussions on bleb-forming procedures, laser treatment and minimally invasive glaucoma surgery.
ASCRS 2026 highlighted a clear shift in glaucoma management, with a move beyond proving efficacy toward refining outcomes, durability and real-world application. Across surgical and medical approaches, the focus is increasingly on sustained intraocular pressure (IOP) control, reduced treatment burden and integration into earlier stages of care.
Watch expert insights into the role of neuroprotection in the prevention of vision loss in glaucoma
The first months of 2026 have already seen a number of interesting studies and reviews published across the ophthalmology literature, setting the stage for another year of progress in the field. Below, we highlight a selection of recent papers from major journals that we found particularly notable over the past few weeks.
World Glaucoma Week 2026 (8–14 March) is a global initiative led by the World Glaucoma Association to raise awareness of glaucoma, which is a the leading causes of irreversible blindness worldwide, and to encourage early detection through regular eye examinations. As glaucoma often develops without noticeable symptoms in its early stages, raising awareness and promoting regular screening amongst the general public remains essential steps in preventing avoidable vision loss.
As we prepare for the launch of touchOPHTHALMOLOGY Future Leaders 2026, one theme has consistently emerged: future leaders do not develop in isolation. Behind every confident clinician, thoughtful academic and emerging opinion leader stands at least one mentor who has helped shaped their direction, discipline and mindset.
A recent study published in the British Journal of Ophthalmology found that the location, size and volume of visual field (VF) defect clusters on an initial test can help predict which defects are likely to recur on future tests, aiding earlier and more reliable identification of glaucomatous damage.
Dr Syed Shoeb Ahmad is a leading glaucoma specialist and practising ophthalmologist based in India. A well-published expert in the field, he is also the creator of 'Glaucoma Specialist Blog: The Glog', an online resource designed to support ophthalmologists at all levels. In this Q&A, he shares his insights on the challenges of early diagnosis, advances in treatment, and the often-overlooked connection between glaucoma and systemic disease.
Encouraging results have emerged from two phase II clinical trials investigating a novel treatment, PER-001, for glaucoma and diabetic retinopathy, two of the most common causes of blindness globally. Delivered via a sustained-release intravitreal implant every six months, PER-001 improved both vision and retinal structure compared with control groups.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.